Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnosis of idiopathic intracranial hypertension - the importance of excluding secondary causes: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Can tendon reflexes be elicited by both stretch and vibration in man?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

PURPOSE: In four large controlled trials with lasmiditan and ubrogepant placebo was administered in the first step to demonstrate an effect on migraine attack. In the same trials the investigators also asked the question: is a second dose of the drug effective in non-responders to the first dose? In this phase patients who received placebo in the first phase of the trial again after 2 hours received another dose of placebo.

CONCLUSION: To be ethical, clinical research requires balancing rigorous science with the protection of human subjects; and it is, in our view, questionable whether placebo was used with "scientific rigor" in the second step of these trials, and this design is not recommended.

Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume42
Issue number1
Pages (from-to)82-85
Number of pages4
ISSN0333-1024
DOIs
Publication statusPublished - Jan 2022

    Research areas

  • lasmiditan, Placebo, ubrogepant

ID: 68917484